title: Chronic myeloid leukemia treatment with Imatinib: An experience from a private tertiary care hospital.
abstract: The data presents 75 chronic myeloid leukemia patients diagnosed over a period 6 years i.e. from 2002 to 2008. The most common presentation was splenomegaly and 97% achieved complete hematological response at median duration of 4.3 weeks. The uniqueness of this study is follow-up with molecular response monitoring. Nearly, 30% patients achieved major molecular response (MMoR) by 12 months. 70% of patients achieved MMoR by median time of 60 months. Only 10% of the patient who achieved MMoR by 18 months had lost their responses subsequently.
authors: Department of Medical Oncology and Research, Rajiv Gandhi Cancer Institute and Research Centre, Rohini, New Delhi, India.
authors: D C
authors: DC
authors: Doval
authors: Department of Medical Oncology and Research, Rajiv Gandhi Cancer Institute and Research Centre, Rohini, New Delhi, India.
authors: Ullas
authors: U
authors: Batra
authors: Department of Medical Oncology and Research, Rajiv Gandhi Cancer Institute and Research Centre, Rohini, New Delhi, India.
authors: Sumit
authors: S
authors: Goyal
authors: Department of Medical Oncology and Research, Rajiv Gandhi Cancer Institute and Research Centre, Rohini, New Delhi, India.
authors: Ajay
authors: A
authors: Sharma
authors: Department of Medical Oncology and Research, Rajiv Gandhi Cancer Institute and Research Centre, Rohini, New Delhi, India.
authors: Saud
authors: S
authors: Azam
authors: Department of Medical Oncology and Research, Rajiv Gandhi Cancer Institute and Research Centre, Rohini, New Delhi, India.
authors: Rashmi
authors: R
authors: Shirali
keywords: Chronic myeloid leukemia; Delhi; Imatinib